In a prospective, randomized trial involving HIV/TB-coinfected patients with CD4 counts >350 cells/mm3, concurrent ART did not improve response to TB therapy.
Current WHO guidelines recommend initiation of antiretroviral therapy (ART) in all HIV-infected patients with active tuberculosis (TB), regardless of CD4-cell count, to delay progression of their HIV infection. In this study, investigators examined whether concurrent ART improves response to TB therapy in patients with high CD4-cell counts. They also assessed the significance of having sputum smears positive for acid-fast bacilli (AFB) after 5 months of TB therapy — a situation that, in the absence of sputum culture results, would qualify as TB-treatment failure, according to WHO guidelines.
A total of 223 HIV-infected patients in Uganda who had CD4 counts >350 cells/mm3 and active pulmonary TB were randomized to receive TB therapy alone (as…
Reviewing Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)